Literature DB >> 26766599

Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.

Robert M Rifkin1, Rafat Abonour2, Jatin J Shah3, Jayesh Mehta4, Mohit Narang5, Howard Terebelo6, Cristina Gasparetto7, Kathleen Toomey8, James W Hardin9, Jane Jie Lu10, Laurie Kenvin10, Shankar Srinivasan10, Robert Knight10, Yasir Nagarwala10, Brian G M Durie11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26766599     DOI： 10.3109/10428194.2015.1132419

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  8 in total

1.  The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Authors:  Gudbjörg Jonsdottir; Sigrún H Lund; Magnus Björkholm; Ingemar Turesson; Malin Hultcrantz; Anna Porwit; Yogesh S Jethava; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-11-22

2.  Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.

Authors:  Sundar Jagannath; Rafat Abonour; Brian G M Durie; Mohit Narang; Howard R Terebelo; Cristina J Gasparetto; Kathleen Toomey; James W Hardin; Lynne Wagner; Amit Agarwal; Shankar Srinivasan; Amani Kitali; E Dawn Flick; Michael Sturniolo; Robert M Rifkin
Journal:  Blood Adv       Date:  2018-07-10

Review 3.  Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?

Authors:  Giovanni Barosi; Robert Peter Gale
Journal:  Leukemia       Date:  2019-01-28       Impact factor: 11.528

4.  Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.

Authors:  Rafat Abonour; Lynne Wagner; Brian G M Durie; Sundar Jagannath; Mohit Narang; Howard R Terebelo; Cristina J Gasparetto; Kathleen Toomey; James W Hardin; Amani Kitali; Craig J Gibson; Shankar Srinivasan; Arlene S Swern; Robert M Rifkin
Journal:  Ann Hematol       Date:  2018-07-29       Impact factor: 3.673

5.  Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.

Authors:  Sebastian Gonzalez-McQuire; Meletios-Athanassios Dimopoulos; Katja Weisel; Walter Bouwmeester; Roman Hájek; Marco Campioni; Craig Bennison; Weiwei Xu; Krystallia Pantiri; Marja Hensen; Evangelos Terpos; Stefan Knop
Journal:  MDM Policy Pract       Date:  2019-01-17

6.  Connect MM Registry as a national reference for United States multiple myeloma patients.

Authors:  Sikander Ailawadhi; Sundar Jagannath; Mohit Narang; Robert M Rifkin; Howard R Terebelo; Kathleen Toomey; Brian G M Durie; James W Hardin; Cristina J Gasparetto; Lynne Wagner; James L Omel; Vivek Kumar; Lihua Yue; Amani Kitali; Amit Agarwal; Rafat Abonour
Journal:  Cancer Med       Date:  2019-11-07       Impact factor: 4.452

Review 7.  Second primary malignancies in multiple myeloma: A review.

Authors:  Christina Poh; Theresa Keegan; Aaron Seth Rosenberg
Journal:  Blood Rev       Date:  2020-09-06       Impact factor: 8.250

Review 8.  Future Directions in Maintenance Therapy in Multiple Myeloma.

Authors:  Sarah A Holstein; Vera J Suman; Jens Hillengass; Philip L McCarthy
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.